Upstream Bio Inc Quick Ratio (UPB) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Upstream Bio Inc   (NASDAQ: UPB)

Upstream Bio Inc 's Quick Ratio

UPB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 17.34 below Upstream Bio Inc average.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Quick Ratio than Upstream Bio Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 160 to 170.

Explain Quick Ratio?
How much Cash & cash equivalents UPB´s has?
What are UPB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UPB/financial-strength
https://api.csimarket.com/api/v1/companies/UPB/fundamentals
https://api.csimarket.com/api/v1/companies/UPB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
UPB Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 0.44 %
Y / Y Cash & cash equivalent Change -44.32 %
Quick Ratio MRQ 17.34
UPB's Total Ranking # 170
Seq. Current Liabilities Change 19.74 %
Seq. Cash & cash equivalent Change -20.64 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 33
Overall Market # 170


Quick Ratio Statistics
High Average Low
46.89 31.16 21.55
(Dec 31 2024)   (Mar 31 2026)




Financial Statements
Upstream Bio Inc 's Current Liabilities $ 12 Millions Visit UPB's Balance sheet
Upstream Bio Inc 's Cash & cash equivalent $ 207 Millions Visit UPB's Balance sheet
Source of UPB's Sales Visit UPB's Sales by Geography


Cumulative Upstream Bio Inc 's Quick Ratio

UPB's Quick Ratio for the trailling 12 Months

UPB Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.63 %
Y / Y Cash & cash equivalent TTM Growth -33.76 %
Quick Ratio TTM 22.51
Total Ranking TTM # 3424
Seq. Current Liabilities TTM Growth 0.11 %
Seq. Cash & cash equivalent TTM Growth -13 %

Quick ratio ranking by company, industry and sector >> Back to UPB Financial Strength Comparisons >> Go to Compare UPB Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $11.96 millions, cumulative Quick Ratio decreased to 22.51 above the UPB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Upstream Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 1877 to 3424.

Explain Quick Ratio?
How much Cash & cash equivalents UPB´s has?
What are UPB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 416
Healthcare Sector # 849
Within the Market # 3424


trailing twelve months Quick Ratio Statistics
High Average Low
12.1 9.19 6.32
(Mar 31 2025)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Vyne Therapeutics Inc   41.29 $ 268.860  Millions$ 6.511  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Xbiotech Inc   39.02 $ 105.037  Millions$ 2.692  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Benitec Biopharma Inc   18.38 $ 176.368  Millions$ 9.594  Millions

Date modified: 2026-11-11T14:04:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.